NovaBay Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Justin Hall

İcra Kurulu Başkanı

US$364.1k

Toplam tazminat

CEO maaş yüzdesi	96.1%
CEO görev süresi	8.9yrs
CEO sahipliği	0.001%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth

Mar 29

CEO Tazminat Analizi

Justin Hall'un ücretlendirmesi NovaBay Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$18m
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$364k	US$350k	-US$17m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$365k	US$350k	-US$16m
Sep 30 2022	n/a	n/a	-US$9m
Jun 30 2022	n/a	n/a	-US$5m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$796k	US$329k	-US$7m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$747k	US$286k	-US$11m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$326k	US$260k	-US$10m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	US$572k	US$260k	-US$7m
Sep 30 2018	n/a	n/a	-US$4m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$6m
Dec 31 2017	US$665k	US$228k	-US$7m

Tazminat ve Piyasa: Justin 'nin toplam tazminatı ($USD 364.15K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 652.28K ).

Tazminat ve Kazançlar: Justin 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Justin Hall (46 yo)

8.9yrs

Görev süresi

US$364,146

Tazminat

Mr. Justin M. Hall, Esq. has been General Counsel at NovaBay Pharmaceuticals, Inc. since December 2015, Corporate Secretary since July 16, 2017 and President and Chief Executive Officer since June 17, 2019...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Justin Hall	President	4.3yrs	US$364.15k	0.0014% $ 48.9
Paul Freiman	Independent Chairman	22.5yrs	US$78.08k	0.0016% $ 55.6
Yenyou Zheng	Independent Director	5.2yrs	US$74.08k	0.0015% $ 54.2
Mijia Wu	Director	8.8yrs	US$40.58k	0.0015% $ 54.2
Pedram Hamrah	Member of Ophthalmic Advisory Board	9.1yrs	Veri yok	Veri yok
Swan Sit	Independent Director	4.9yrs	US$59.08k	0.0015% $ 54.2
Komal Thakore	Member of the Optometry Advisory Board	4yrs	Veri yok	Veri yok
Amr Kouchouk	Member of the Ophthalmic Advisory Board	4yrs	Veri yok	Veri yok
John Aljian	Member of the Ophthalmic Advisory Board	4yrs	Veri yok	Veri yok
Laura Periman	Member of the Ophthalmic Advisory Board	4yrs	Veri yok	Veri yok
Milap Mehta	Member of the Ophthalmic Advisory Board	4yrs	Veri yok	Veri yok
Melanie Bennett-Sims	Member of the Ophthalmic Advisory Board	4yrs	Veri yok	Veri yok

4.1yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NBY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

NovaBay Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024

Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023

Novabay Pharmaceuticals, Inc. Approves to Elect Mijia (Bob) Wu as Director

NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023

Novabay Pharmaceuticals, Inc. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Consensus EPS estimates fall by 131%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million.

Consensus revenue estimates decrease by 15%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

NYSE American Accepts NovaBay Pharmaceuticals Plan of Compliance

No longer forecast to breakeven

NovaBay Pharmaceuticals Provides Non-Compliance Update

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024

Consensus EPS estimates upgraded to US$0.27 loss, revenue downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY).

New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.

New minor risk - Share price stability

NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft

Consensus EPS estimates fall by 56%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023

Novabay Pharmaceuticals, Inc. Approves to Elect Mijia (Bob) Wu as Director

NovaBay Pharmaceuticals, Inc. Announces DERMAdoctor's KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to Be Featured on QVC at a Special Price

NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023

Consensus revenue estimates increase by 20%

No longer forecast to breakeven

NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023

Novabay Pharmaceuticals, Inc. Announces Executive Changes

Consensus forecasts updated

Consensus EPS estimates fall by 57%

Price target decreased to US$39.88

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

NovaBay Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novabay Pharmaceuticals, Inc. Announces Newest Addition to the Dermadoctor Picture Porefect Collection 15% Niacinamide Pore Minimizing Serum

NovaBay Pharmaceuticals, Inc.’ Avenova and DERMAdoctor Products to be Featured During the October 11-12 Amazon Prime Early Access Sale

NovaBay Pharmaceuticals Receives NYSE American Notice Regarding Low Share Price

Consensus EPS estimates fall by 13%

Price target decreased to US$2.80

NovaBay Pharmaceuticals, Inc. announced that it expects to receive $3.25 million in funding

Consensus EPS estimates fall by 14%

Price target decreased to US$2.98

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Novabay Pharmaceuticals, Inc. Announces Availability of Select Dermadoctor Products

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

NovaBay Pharmaceuticals, Inc. Expands DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations

NovaBay Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

NovaBay Pharmaceuticals, Inc. Introduces Hydrating Cleansing Oil to Its Dermadoctor Calm Cool + Corrected Product Line

Full year 2021 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 11, 2022

Novabay Pharmaceuticals Announces Changes to Its Board of Directors

Novabay Pharmaceuticals Expands Its Eyecare Product Portfolio with the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms

Forecast to breakeven in 2024

Novabay Pharmaceuticals, Inc. Announces DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance

Chief Product Officer recently bought US$125k worth of stock

Price target increased to US$3.10

Consensus forecasts updated

Third quarter 2021 earnings released: US$0.051 loss per share (vs US$0.08 loss in 3Q 2020)

Price target increased to US$2.85